Development and full validation of an LC–MS/MS methodology to quantify capmatinib (INC280) following intragastric administration to rats
Authors:
- 10 December 2019
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 34 (3) , e4768
Abstract
A highly sensitive, specific and simple LC–MS/MS method for quantification of capmatinib (INC280) in rat plasma was presented. The LC–MS/MS method was validated in terms of specificity and selectivity, linearity, accuracy and precision, matrix effect, extraction recovery, dilution integrity, carryover and stability as per the US Food and Drug Administration's bioanalytical method validation guideline. The validated assay was applied for quantification of capmatinib from a pharmacokinetic study in rats following oral administration at the doses of 1.0, 3.0 and 9.0 mg/kg. The calibration curve ranges from 1 to 2000 ng/ml with desirable linearity and r2 > 0.99. The intra‐ and inter‐batch accuracies were within 99.24–103.59 and 97.76–102.83% with coefficients of variation 5.08–7.36 and 3.18–4.99%, respectively. No significant interference was observed by endogenous peak at the retention time of capmatinib and IS. The assay was free from any matrix effect and showed precise recovery across the calibration curve range, and samples were stable under all experimental conditions. The validated assay was successfully applied to analyze plasma samples of pharmacokinetic study in rat to determine the concentration of capmatinib. In summary, a novel method for analyzing capmatinib in rat plasma has been successfully validated and is now being utilized for quantification of capmatinib from pre‐clinical studies.Keywords
This publication has 11 references indexed in Scilit:
- Evaluation of pharmacokinetics, bioavailability and urinary excretion of scopolin and its metabolite scopoletin in Sprague Dawley rats by liquid chromatography–tandem mass spectrometryBiomedical Chromatography, 2019
- Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor CapmatinibCancer Research and Treatment, 2019
- Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET ActivationClinical Cancer Research, 2019
- Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumorsCancer Science, 2019
- Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC “capitulate”?Translational Lung Cancer Research, 2018
- Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2018
- Preliminary activity of capmatinib with gefitinib in NSCLCThe Lancet Oncology, 2018
- Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung CancerClinical Lung Cancer, 2017
- The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in miceToxicology Letters, 2016
- Simultaneous determination of paeoniflorin from total glucosides of paeony in Sprague–Dawley rats and spontaneously hypertensive rats by high‐performance liquid chromatography–tandem mass spectrometry: in vivo and in vitro studiesBiomedical Chromatography, 2016